Overview
Hyposmia-nasal and ocular hypoplasia-hypogonadotropic hypogonadism syndrome, also known as Bosma arhinia microphthalmia syndrome (BAMS), is an extremely rare congenital condition characterized by the triad of complete absence of the nose (arhinia) or severe nasal hypoplasia, ocular defects (microphthalmia or anophthalmia), and hypogonadotropic hypogonadism. The condition is present from birth and affects multiple body systems including the craniofacial structures, the eyes, the olfactory system, and the reproductive endocrine axis. Patients typically have absent or severely underdeveloped external nasal structures, absent or rudimentary nasal passages, and absent paranasal sinuses. The olfactory system is affected, leading to hyposmia (reduced sense of smell) or anosmia (complete absence of smell). Eye abnormalities range from small eyes (microphthalmia) to absent eyes (anophthalmia), with variable degrees of visual impairment. Hypogonadotropic hypogonadism results from deficient gonadotropin-releasing hormone signaling, leading to delayed or absent puberty and potential infertility. The genetic basis of BAMS has been linked to mutations in the SMCHD1 gene, which plays a role in epigenetic regulation and chromatin organization. The condition appears to arise from de novo dominant mutations in most reported cases. Management is multidisciplinary and symptomatic, involving reconstructive craniofacial surgery to address nasal defects, ophthalmologic care for ocular abnormalities (including prosthetic eyes when needed), airway management, and hormone replacement therapy to induce puberty and address hypogonadism. Fertility treatment may be considered in adulthood. Due to the extreme rarity of this condition, with fewer than 50 cases reported in the medical literature, management is guided primarily by case reports and expert opinion rather than clinical trials.
Clinical phenotype terms— hover any for plain English:
Autosomal dominant
Passed on from just one parent; each child has about a 50% chance of inheriting it
Neonatal
Begins at or shortly after birth (first 4 weeks)
Treatments
No FDA-approved treatments are currently listed for Hyposmia-nasal and ocular hypoplasia-hypogonadotropic hypogonadism syndrome.
View clinical trials →Clinical Trials
View all trials with filters →No actively recruiting trials found for Hyposmia-nasal and ocular hypoplasia-hypogonadotropic hypogonadism syndrome at this time.
New trials open frequently. Follow this disease to get notified.
Specialists
View all specialists →No specialists are currently listed for Hyposmia-nasal and ocular hypoplasia-hypogonadotropic hypogonadism syndrome.
Treatment Centers
8 centersBaylor College of Medicine Rare Disease Center ↗
Baylor College of Medicine
📍 Houston, TX
🏥 NORDStanford Medicine Rare Disease Center ↗
Stanford Medicine
📍 Stanford, CA
🔬 UDNNIH Clinical Center Undiagnosed Diseases Program ↗
National Institutes of Health
📍 Bethesda, MD
🔬 UDNUCLA UDN Clinical Site ↗
UCLA Health
📍 Los Angeles, CA
🔬 UDNBaylor College of Medicine UDN Clinical Site ↗
Baylor College of Medicine
📍 Houston, TX
🔬 UDNHarvard/MGH UDN Clinical Site ↗
Massachusetts General Hospital
📍 Boston, MA
🏥 NORDMayo Clinic Center for Individualized Medicine ↗
Mayo Clinic
📍 Rochester, MN
👤 Mayo Clinic Center for Individualized Medicine
🏥 NORDUCLA Rare Disease Day Program ↗
UCLA Health
📍 Los Angeles, CA
Travel Grants
No travel grants are currently matched to Hyposmia-nasal and ocular hypoplasia-hypogonadotropic hypogonadism syndrome.
Community
No community posts yet. Be the first to share your experience with Hyposmia-nasal and ocular hypoplasia-hypogonadotropic hypogonadism syndrome.
Start the conversation →Latest news about Hyposmia-nasal and ocular hypoplasia-hypogonadotropic hypogonadism syndrome
No recent news articles for Hyposmia-nasal and ocular hypoplasia-hypogonadotropic hypogonadism syndrome.
Follow this condition to be notified when news becomes available.
Caregiver Resources
NORD Caregiver Resources
Support, advocacy, and financial assistance for caregivers of rare disease patients.
Mental Health Support
Rare disease caregiving can be isolating. Connect with counseling and peer support.
Family & Caregiver Grants
Financial assistance programs specifically for caregivers of rare disease patients.
Social Security Disability
Learn how rare disease patients may qualify for SSDI/SSI benefits.
Common questions about Hyposmia-nasal and ocular hypoplasia-hypogonadotropic hypogonadism syndrome
What is Hyposmia-nasal and ocular hypoplasia-hypogonadotropic hypogonadism syndrome?
Hyposmia-nasal and ocular hypoplasia-hypogonadotropic hypogonadism syndrome, also known as Bosma arhinia microphthalmia syndrome (BAMS), is an extremely rare congenital condition characterized by the triad of complete absence of the nose (arhinia) or severe nasal hypoplasia, ocular defects (microphthalmia or anophthalmia), and hypogonadotropic hypogonadism. The condition is present from birth and affects multiple body systems including the craniofacial structures, the eyes, the olfactory system, and the reproductive endocrine axis. Patients typically have absent or severely underdeveloped exte
How is Hyposmia-nasal and ocular hypoplasia-hypogonadotropic hypogonadism syndrome inherited?
Hyposmia-nasal and ocular hypoplasia-hypogonadotropic hypogonadism syndrome follows a autosomal dominant inheritance pattern. Genetic counseling can help families understand recurrence risk and testing options.
At what age does Hyposmia-nasal and ocular hypoplasia-hypogonadotropic hypogonadism syndrome typically begin?
Typical onset of Hyposmia-nasal and ocular hypoplasia-hypogonadotropic hypogonadism syndrome is neonatal. Age of onset can vary across affected individuals.